Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

NCT03731715 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.

NCT NCT03731715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03731715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Lead sponsor
SK Life Science, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 7, 2019
Completion date
June 29, 2022
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lennox gastaut syndrome